BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 15293997)

  • 1. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
    Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
    J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
    Adane L; Bharatam PV; Sharma V
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
    Adane L; Bharatam PV
    J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition.
    Adane L; Patel DS; Bharatam PV
    Chem Biol Drug Des; 2010 Jan; 75(1):115-26. PubMed ID: 19895504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
    Rastelli G; Pacchioni S; Sirawaraporn W; Sirawaraporn R; Parenti MD; Ferrari AM
    J Med Chem; 2003 Jul; 46(14):2834-45. PubMed ID: 12825927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase.
    Gangjee A; Lin X
    J Med Chem; 2005 Mar; 48(5):1448-69. PubMed ID: 15743188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
    Krovat EM; Langer T
    J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
    Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
    J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore modeling of substituted 1,2,4-Trioxanes for quantitative prediction of their antimalarial activity.
    Gupta AK; Chakroborty S; Srivastava K; Puri SK; Saxena AK
    J Chem Inf Model; 2010 Aug; 50(8):1510-20. PubMed ID: 20726605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods.
    Xiao Z; Varma S; Xiao YD; Tropsha A
    J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.
    Debnath AK
    J Med Chem; 2003 Oct; 46(21):4501-15. PubMed ID: 14521412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative structure activity relationship study of 2,4,6-trisubstituted-s-triazine derivatives as antimalarial inhibitors of Plasmodium falciparum dihydrofolate reductase.
    Ojha H; Gahlot P; Tiwari AK; Pathak M; Kakkar R
    Chem Biol Drug Des; 2011 Jan; 77(1):57-62. PubMed ID: 20958921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates.
    Bhattacharjee AK; Hartell MG; Nichols DA; Hicks RP; Stanton B; van Hamont JE; Milhous WK
    Eur J Med Chem; 2004 Jan; 39(1):59-67. PubMed ID: 14987834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
    Sirichaiwat C; Intaraudom C; Kamchonwongpaisan S; Vanichtanankul J; Thebtaranonth Y; Yuthavong Y
    J Med Chem; 2004 Jan; 47(2):345-54. PubMed ID: 14711307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase.
    Kumar G; Banerjee T; Kapoor N; Surolia N; Surolia A
    IUBMB Life; 2010 Mar; 62(3):204-13. PubMed ID: 20131353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-based molecular modeling study on a chemically diverse series of cholecystokinin-B/gastrin receptor antagonists: generation of predictive model.
    Chopra M; Mishra AK
    J Chem Inf Model; 2005; 45(6):1934-42. PubMed ID: 16309300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.
    Zampieri D; Mamolo MG; Laurini E; Florio C; Zanette C; Fermeglia M; Posocco P; Paneni MS; Pricl S; Vio L
    J Med Chem; 2009 Sep; 52(17):5380-93. PubMed ID: 19673530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.